Effective from tomorrow,
01 Aug 15, Celgene Australia’s
Pomalyst (pomalidomide) will be
PBS listed (Authority Requred) in
combination with dexamethasone
for the treatment of patients
with relapsed and refractory
multiple myeloma who have failed
prior treatment regimens with
lenalidomine and bortezomib.
The once daily capsule is the
first next-generation myeloma
treatment to offer prolonged
survival and maintain quality of life.The above article was sent to subscribers in Pharmacy Daily's issue from 31 Jul 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Jul 15
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.